Recent studies have revealed that posttranslational modification of the transcription factor c-Jun plays a functional and necessary role in the mechanism of transformation by activated c-Ha-Ras. We have extended these studies to show that a similar mechanism is operating in v-sis transformed cells and that multiple transcription factors such as other Jun and Fos family members as well as unrelated transcription factors like Egr-1 also exhibit substantially increased phosphorylation. Preliminary studies have been carried out in model cells which exhibit inducible, complete and reversible transformation by an inducible sis construct. Phosphorylation of these factors does not occur in normally growing cells but is constant in sis-transformed cells and is quantitatively reversible suggesting transformation-specific mode of regulation. Preliminary studies using transdominant negative mutations show that c-raf-1 and c-ras, both reported to activated by PDGF, are required for transformation by v-sis.
Specific Aim #1 is to test whether the model cell system exhibits an autocrine mechanism of transformation.
Specific Aim #2 is to use these cells to test the hypothesis that phosphorylation of c-Jun and family members is transformation-specific, mediates transformation by v-sis, requires, and is necessary for, the action of c-ras and c-raf-1 according to the general signal transduction scheme:PDGF-activated receptor, C ras, c raf-1, c- Jun(ser63,73)-(PO4)2, AP-1 activity and other transforming events. The phosphorylation sites will be further characterized by two-dimensional phosphopeptide mapping in combination with microsequencing.
Specific Aim #3 is to test whether phosphorylation may be important in human tumors by determining whether phosphorylated transcription factors occur in human tumor lines and fresh tumor tissue of breast, ovary, prostate, osteosarcomas and glioblastomas where PDGF/sis autocrine mechanism has been implicated. Knowledge of transformation-specific regulatory events such as phosphorylations may provide targets of specific intervention which will not alter normal growth and function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA063783-03
Application #
2105861
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1993-09-22
Project End
1997-06-30
Budget Start
1995-07-07
Budget End
1996-06-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Sidney Kimmel Cancer Center
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Hayakawa, Jun; Mittal, Shalu; Wang, Yipeng et al. (2004) Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 16:521-35
Hayakawa, Jun; Depatie, Chantal; Ohmichi, Masahide et al. (2003) The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 278:20582-92
Yang, Yong-Min; Bost, Frederic; Charbono, Wilfried et al. (2003) C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9:391-401
Cripe, L D; Gelfanov, V M; Smith, E A et al. (2002) Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. Leukemia 16:799-812
Gjerset, R; Haghighi, A; Lebedeva, S et al. (2001) Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods. Methods Mol Biol 175:495-520
Potapova, O; Gorospe, M; Bost, F et al. (2000) c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 275:24767-75
de Belle, I; Mercola, D; Adamson, E D (2000) Method for cloning in vivo targets of the Egr-1 transcription factor. Biotechniques 29:162-9
Liu, C; Yao, J; Mercola, D et al. (2000) The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 275:20315-23
Hayakawa, J; Ohmichi, M; Kurachi, H et al. (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648-54
Liu, C; Yao, J; de Belle, I et al. (1999) The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem 274:4400-11

Showing the most recent 10 out of 22 publications